Case-control study on severe risk factors in COVID-19 patients in Fujian Province

CHEN Guang-min; LAN Mei-fang; CHEN Xiao-hong; XIE Jian-feng; OU Jian-ming; ZHENG Kui-cheng

doi:10.16462/j.cnki.zhjbkz.2021.11.016

Volume 25 Issue 11

Nov. 2021

Turn off MathJax

Article Contents

Article Navigation > CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION > 2021 > 25(11): 1327-1331

CHEN Guang-min, LAN Mei-fang, CHEN Xiao-hong, XIE Jian-feng, OU Jian-ming, ZHENG Kui-cheng. Case-control study on severe risk factors in COVID-19 patients in Fujian Province[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2021, 25(11): 1327-1331. doi: 10.16462/j.cnki.zhjbkz.2021.11.016

Citation:

CHEN Guang-min, LAN Mei-fang, CHEN Xiao-hong, XIE Jian-feng, OU Jian-ming, ZHENG Kui-cheng. Case-control study on severe risk factors in COVID-19 patients in Fujian Province[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2021, 25(11): 1327-1331. doi: 10.16462/j.cnki.zhjbkz.2021.11.016

Citation:

CHEN Guang-min, LAN Mei-fang, CHEN Xiao-hong, XIE Jian-feng, OU Jian-ming, ZHENG Kui-cheng. Case-control study on severe risk factors in COVID-19 patients in Fujian Province[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2021, 25(11): 1327-1331. doi: 10.16462/j.cnki.zhjbkz.2021.11.016

PDF( 858 KB)

Case-control study on severe risk factors in COVID-19 patients in Fujian Province

doi: 10.16462/j.cnki.zhjbkz.2021.11.016

CHEN Guang-min^{1, 2, 3},
LAN Mei-fang^{1, 2, 3},
CHEN Xiao-hong^{1, 2, 3},
XIE Jian-feng^{1, 2, 3},
OU Jian-ming^{1, 2, 3},
ZHENG Kui-cheng^{4
,
,}

1.
Teaching Base of the School of Public Health of Fujian Medical University, Fuzhou 350001, China
2.
Fujian Center for Disease Control and Prevention, Fuzhou 350001, China
3.
Fujian Key Laboratory of Human and Animal Disease Research, Fuzhou 350001, China
4.
Respiratory Department of Fuzhou Pulmonary Hospital, Fuzhou 350001, China

Funds: Fujian Provincial Natural Science Foundation Project (2021R0111, 2020J01094); Special Project of the Central Government Guiding Local Science and Technology Development (2021L3018); Fujian Science and Technology Innovation Platform Construction Project (2019Y2001)

More Information

Corresponding author: ZHENG Kui-cheng, E-mail: kingdadi9909@126.com
Received Date: 2021-05-24
Rev Recd Date: 2021-08-10

Available Online: 2021-12-04

Publish Date: 2021-11-10

Abstract

Abstract

Objective To analyze the epidemiological characteristics and laboratory tests of coronavirus diseases 2019(COVID-19) cases in Fujian province and to explore the risk factors for their progression to severe cases. Methods The clinical and epidemiological data of COVID-19 confirmed patients with clinical final outcome (including recovery death, etc.) from January 22 to March 7 in 2020 in Fujian were collected. The risk factors of the severe cases were analyzed by univariate and multivariate Logistic regression. Results Up to March 7, 2020, a total of 231 patients were collected in Fujian province, among which, 39(16.88%) were severe and critical cases. The univariate analysis showed that most patients in the severe group had underlying diseases (71.80%), which was significantly higher than that in the non-severe group (34.40%) (χ² =18.808, P < 0.001). Among them, hypertension, cardiovascular disease, lung disease, other chronic diseases and other factors were statistically different between the two groups (all P < 0.05).Then, numbers of hematological tests were statistical differences between the two groups. Multivariate Logistic regression analysis revealed that age≥65 years old (OR=17.067, 95%CI: 2.640-110.327), low level of lymphocyte (OR=4.731, 95%CI: 1.175-19.046), liver dysfunction (OR=12.458, 95%CI: 2.559-60.649), high level of calcitonin (OR=3.577, 95%CI: 1.733-7.384) and high level of C-reaction protein (OR=2.354, 95%CI: 1.012-5.478) were risk factors for the progression of COVID-19 patients to severe illness. The obtained regression equation fits the training sample well (AUC=0.941). Conclusions Low level of lymphocyte, liver dysfunction, high level of calcitonin and high level of C-reaction protein could be used as the early warning indicators for severe cases. More attention should be paid to elderly patients age≥65 years old and patients with the above laboratory test abnormality and timely and effective treatment should be taken.
- COVID-19,
- Severecase,
- Risk factors,
- Case control study

FullText(HTML)

References(17)

References

[1]	Huang CL, Wang YM, Li XW, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020, 395(10223): 497-506. DOI: 10.1016/s0140-6736(20)30183-5.
[2]	World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard[EB/OL]. (2021-05-09)[2021-05-09]. https://covid19.who.int/.
[3]	凌云, 徐水宝, 林逸骁, 等. 新型冠状病毒肺炎患者重症化危险因素的临床分析[J]. 上海医药, 2020, 41(S1): 58-59. https://www.cnki.com.cn/Article/CJFDTOTAL-SYIY2020S1025.htm Ling Y, Xu SB, Lin YX, et al. Clinical analysis of risk factors for severe patients with corona virus disease 2019[J]. Shanghai Med Pharm J, 2020, 41(S1): 58-59. https://www.cnki.com.cn/Article/CJFDTOTAL-SYIY2020S1025.htm
[4]	中华人民共和国国家卫生健康委员会办公厅, 国家中医药管理局办公室. 新型冠状病毒肺炎诊疗方案(试行第七版)[J]. 江苏中国医药, 2020, 52(4): 1-6. DOI: 10.19844/j.cnki.1672-397x.2020.04.001. General Office of the National Health Commission of the People 's Republic of China, Office of National Administration of Traditional Chinese Medicine. Diagnosis and treatment protocol for COVID-19 trial version 7[J]. Jiangsu J Tradit Chin Med, 2020, 52(4): 1-6. DOI: 10.19844/j.cnki.1672-397x.2020.04.001.
[5]	何权瀛, 高莹慧. 关于吸烟问题若干名词定义[J]. 中华结核和呼吸杂志, 2009, 32(1): 56. DOI: 10.3760/cma.j.issn.1001-0939.2009.01.008. He QY, Gao YH. Definitions of several terms on smoking[J]. Chin J Tuberc Respir Dis, 2009, 32(1): 56. DOI: 10.3760/cma.j.issn.1001-0939.2009.01.008.
[6]	中华人民共和国国家卫生健康委员会办公厅, 国家中医药管理局办公室. 新型冠状病毒肺炎诊疗方案(试行第八版)[J]. 中国医药, 2020, 15(10): 1494-1499. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGYG202010002.htm General Office of the National Health Commission of the People 's Republic of China, Office of National Administration of Traditional Chinese Medicine. Diagnosis and treatment of Corona virus disease-19 (8th trial edition)[J]. China Med, 2020, 15(10): 1494-1499. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGYG202010002.htm
[7]	Liu XQ, Xue S, Xu JQ, et al. Clinical characteristics and related risk factors of disease severity in 101 COVID-19 patients hospitalized in Wuhan, China[J]. Acta Pharmacol Sin, 2021: 1-12. DOI: 10.1038/s41401-021-00627-2.
[8]	Yang XB, Yu Y, Xu JQ, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study[J]. Lancet Respir Med, 2020, 8(5): 475-481. DOI: 10.1016/s2213-2600(20)30079-5.
[9]	彭志行, 陈旭峰, 胡钦勇, 等. 新型冠状病毒肺炎患者重症转归风险预测[J]. 中华流行病学杂志, 2020, 41(10): 1595-1600. DOI: 10.3760/cmaj.cn112338-20200331-00479. Peng ZX, Chen XF, Hu QY, et al. Prediction of severe outcomes of patients with COVID-19[J]. Chin J Epidemiol, 2020, 41(10): 1595-1600. DOI: 10.3760/cmaj.cn112338-20200331-00479.
[10]	中华预防医学会新型冠状病毒肺炎防控专家组. 新型冠状病毒肺炎流行病学特征的最新认识[J]. 中国病毒病杂志, 2020, 10(2): 86-92. DOI: 10.16505/j.2095-0136.2020.0015. Special Expert Group for Control of the Epidemic of Novel Corona virus Pneumonia, An update on the epidemiological characteristics of novel coronavirus pneumonia (COVID-19)[J]. Chin J Viral Dis, 2020, 10(2): 86-92. DOI: 10.16505/j.2095-0136.2020.0015.
[11]	曾旻敏, 田克卿, 刘天, 等. 新型冠状病毒肺炎病例重症化影响因素及早期临床特征[J]. 中华疾病控制杂志, 2020, 24(7): 835-839. DOI: 10.16462/j.cnki.zhjbkz.2020.07.017. Zeng MM, Tian KQ, Liu T, et al. Analysis of influencing factors and early clinical features of severe cases of COVID-19[J]. Chin J Dis Control Prev, 2020, 24(7): 835-839. DOI: 10.16462/j.cnki.zhjbkz.2020.07.017.
[12]	孙昼, 陈珺芳, 杨旭辉, 等. 43例新型冠状病毒肺炎重症患者的危险因素分析[J]. 中国病毒病杂志, 2020, 10(6): 455-457. DOI: 10.16505/j.2095-0136.2020.0035. Sun Z, Chen JF, Yang XH, et al. Retrospective study of risk factors of 43 patients with severe coronavirus disease 2019 pneumonia[J]. Chin J Viral Dis, 2020, 10(6): 455-457. DOI: 10.16505/j.2095-0136.2020.0035.
[13]	Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China[J]. N Engl J Med, 2020, 382(18): 1708-1720. DOI: 10.1056/nejmoa2002032.
[14]	Xie JY, Wang Q, Xu YY, et al. Clinical characteristics, laboratory abnormalities and CT findings of COVID-19 patients and risk factors of severe disease: a systematic review and meta-analysis[J]. Ann Palliat Med, 2021, 10(2): 1928-1949. DOI: 10.21037/apm-20-1863.
[15]	倪力, 邓雪梅, 黄勉, 等. 新型冠状病毒肺炎严重程度的危险因素分析[J]. 临床肺科杂志, 2021, 26(1): 139-140, 146. https://www.cnki.com.cn/Article/CJFDTOTAL-LCFK202101031.htm Ni L, Deng XM, Huang M, et al. Risk factors for disease severity of COVID-19[J]. J Clin Pulm Med, 2021, 26(1): 139-140, 146. https://www.cnki.com.cn/Article/CJFDTOTAL-LCFK202101031.htm
[16]	Li Q, Xie Y, Cui Z, et al. Analysis of peripheral blood IL-6 and leukocyte characteristics in 364 COVID-19 patients of Wuhan[J]. Front Immunol, 2020, 11: 559716. DOI: 10.3389/fimmu.2020.559716.
[17]	Cai QX, Huang DL, Yu H, et al. COVID-19: Abnormal liver function tests[J]. J Hepatol, 2020, 73(3): 566-574. DOI: 10.1016/j.jhep.2020.04.006.